Trade-Ideas: Mylan (MYL) Is Today's Pre-Market Leader Stock
Trade-Ideas LLC identified Mylan ( MYL) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Mylan as such a stock due to the following factors:
- MYL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $252.8 million.
- MYL traded 146,826 shares today in the pre-market hours as of 7:54 AM.
- MYL is up 4.6% today from yesterday's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in MYL with the Ticky from Trade-Ideas. See the FREE profile for MYL NOW at Trade-Ideas
More details on MYL: Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. MYL has a PE ratio of 38. Currently there are 5 analysts that rate Mylan a buy, no analysts rate it a sell, and 5 rate it a hold. The average volume for Mylan has been 5.9 million shares per day over the past 30 days. Mylan has a market cap of $21.8 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.28 and a short float of 9.4% with 6.12 days to cover. Shares are down 21.2% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Mylan as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 3.0%. Since the same quarter one year prior, revenues rose by 19.6%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Pharmaceuticals industry average. The net income increased by 2.9% when compared to the same quarter one year prior, going from $189.20 million to $194.60 million.
- Net operating cash flow has significantly increased by 415.00% to $652.00 million when compared to the same quarter last year. In addition, MYLAN NV has also vastly surpassed the industry average cash flow growth rate of -28.37%.
- The gross profit margin for MYLAN NV is rather high; currently it is at 58.40%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 7.81% trails the industry average.
- You can view the full Mylan Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
